qualitative research grounded in SEC filings & market-flow signals Quant side · QuantOrb.pro ↗

STE — Tear Sheet

STERIS plc · Provides infection prevention and surgical products, including sterilization equipment and consumables.

Health Care Equipment · Health Care · covers US session 2026-10-23 · Tear sheet created 21 days ago

AdCho Opinion

Underweight

Bottom Line

Underweight: fundamentals and guidance hold, but the tape sits pinned on the upper Bollinger band ahead of a print where Xodus financing stays undisclosed — trim into strength, hedge the rest, re-underwrite only after disclosure

Market Sentiment Summary

AdCho's read on STE sentiment for this window is Mildly Bullish, scored 6.0/10, with Low confidence — we keep that caution intact.

STE daily chart

sessions

Loading chart…

How to read this chart
  1. Top: price candles (green up, red down) with Bollinger Bands (20, 2) in dashed orange, the 50-session average in blue, the 200-session average in dashed orange, and volume bars along the bottom
  2. Middle: RSI (14), Wilder’s method, with dashed guides at 30 and 70
  3. Bottom: MACD (12, 26, 9): MACD line, dashed signal line and a green/red histogram

Prices: Yahoo Finance daily bars, split- and dividend-adjusted; indicators computed on two years of history, then the window is cut · as of latest session · Chart by TradingView Lightweight Charts™ © TradingView, Inc.

Share this tear sheet

X Facebook LinkedIn Reddit WhatsApp Email

Executive Summary

  • The stance is Underweight: a reduced, hedged position rather than an exit, with fundamentals keeping the name in the portfolio
  • The constructive leg is real: a solid quarter with guidance affirmed, share gains in consumables and services, and a cleaner three-segment portfolio
  • The counterweight is a low-twenties earnings multiple on a soft free-cash-flow base, with organic growth stepping down from the prior pace
  • The deciding stack is the early-November print, where Xodus financing and accretion remain undisclosed
  • The reaction record shows two adverse earnings gaps this year, one on a good quarter, so size and hedges carry the tail risk
  • The retained, hedged holding reads as a free option on the deal disclosure, with healthcare the bid lane while tech bleeds
  • We re-underwrite fully only once the print delivers the financing terms

Market Sentiment

  • We read sentiment as Mildly Bullish, scored six of ten, with low confidence — and we keep that restraint rather than grading it up
  • Every genuine signal in the window leans the same mildly constructive way, and none carries a bearish STE datapoint
  • The news sample is thin — a handful of headlines, all constructive or neutral, orbiting the upcoming print
  • The social leg is hollow: a wall of WhatsApp recruitment spam with zero engagement, a holder-protection red flag rather than demand
  • The only genuine social trace was one unlabeled volume-observation post, an activity signal wearing no directional label
  • Money flow reads elevated on a continuation signal and institutional adds lean constructive, but the holdings picture is months stale
  • We weight the sentiment leg light: it rests on thin news and screens, and the fastest confirmation channel is simply absent

News

get_news

Steris inks $2.1B Xodus buyout to expand consumables portfolio

Trade coverage of the definitive agreement for STERIS to acquire Xodus Medical, a specialty surgical products business, deepening the Healthcare segment's consumables portfolio.

AdCho insight: The deal deepens the exact consumables stream management credited with share gains, but the sheet's underweight turns on the still-undisclosed multiple and financing, so this headline sharpens the event stack rather than resolving it.

get_news

STERIS to Host a Conference Call for Fiscal 2027 Second Quarter on November 5, 2026

Calendar announcement of the fiscal 2027 second-quarter conference call, the event anchoring the window's coverage.

AdCho insight: This is the sheet's pivot date — the first venue for Xodus financing and accretion detail — and the underweight sizing and hedging are built explicitly around it.

get_news

Reasons to Add STE Stock to Your Portfolio Right Now

An explicitly bullish, actionable research piece framing STE as an add right now.

AdCho insight: The strongest bullish voice in the window; the sheet holds its reduced stance anyway because price, the event stack and a soft free-cash-flow base outweigh one constructive call, with independent cautionary pieces in the same tape.

get_news

Earnings Preview: What To Expect From STERIS' Report

Anticipatory pre-print coverage framing expectations into the fiscal second-quarter report.

AdCho insight: Preview coverage confirms the print is the window's center of gravity; the sheet's stance prices the asymmetric reaction record this name showed even on good news this year.

get_global_news

Stock market today: Dow sinks 600 points, S&P 500, Nasdaq drop to cap a volatile week, oil prices rise

End-of-week tape coverage of a sharp, tech-led selloff capping a volatile week, with oil higher.

AdCho insight: The macro tape the sheet trades against: risk-off in tech with healthcare acting as the bid lane, which supports a trimmed defensive holding rather than a full exit.

get_global_news

Dow and Small Caps Climb Weekly While Nasdaq Slips on Megacap Earnings Charges

Weekly wrap: the Dow and small caps climbed while the Nasdaq slipped on megacap earnings charges.

AdCho insight: The tape's character reads as rotation rather than liquidation — consistent with the sheet trimming into strength while defensive healthcare demand persists.

Social

No in-window X posts for this session.

Polymarket

Will no Fed rate cuts happen in 2026?
Yes 96% ($9,108,575 volume, resolves 2027-01-01, 1-week -0.4pp)

Will 11 Fed rate cuts happen in 2026?
Yes 0% ($5,319,017 volume, resolves 2027-01-01)

Will 10 Fed rate cuts happen in 2026?
Yes 0% ($4,973,199 volume, resolves 2027-01-01)

Will 9 Fed rate cuts happen in 2026?
Yes 0% ($4,308,913 volume, resolves 2027-01-01)

Will 6 Fed rate cuts happen in 2026?
Yes 0% ($4,232,530 volume, resolves 2027-01-01)

Will 12 or more Fed rate cuts happen in 2026?
Yes 0% ($4,156,117 volume, resolves 2027-01-01)

Live odds at run time (UTC) — macro market context, not company-specific; the rates, recession and fiscal-deadline odds every equity reads against. Not signals to act on. Topic: “Fed rate cut”.

Management Sentiment & Catalyst Highlights

  • Management's tone reads plainly pleased and steady: stable underlying demand, with revenue and earnings expectations for the year explicitly unchanged
  • The quarter's story is Healthcare-led: share gains in consumables and services, underpinned by solid order growth for capital equipment
  • Growth reads solid in the round — revenue up seven percent, organic a touch below that, adjusted earnings up about eleven percent
  • The company announced the $2.1 billion Xodus acquisition to deepen the exact consumables stream management credits, a large deployment after the Dental exit
  • A targeted restructuring around a new Formulated Chemistries Center of Excellence in North Carolina adds a margin story to watch
  • A raised dividend and a cleaner three-segment portfolio round out a constructive capital posture
  • The visible catalyst is the November 5 call — the first venue for Xodus financing and accretion detail, with guidance held rather than raised

Key Risk Factors

  • The primary risk is the event stack: Xodus financing and accretion stay undisclosed into the early-November print against a punishing reaction record
  • Two adverse earnings gaps this year, one on a good quarter, compounded deeply, so only size and hedges carry the tail
  • A comparable transformative consumables deal in the sector's history produced a large reported quarterly loss during integration, a live template for the risk
  • The tape is its own risk: price pinned on the upper Bollinger band, RSI elevated, and the last moving-average reclaim died at first resistance
  • Valuation leaves no cushion — a low-twenties multiple on a soft free-cash-flow base — while organic growth decelerates and operating cash flow softened
  • Rates press the second leg: a hot inflation print, a higher effective policy rate, and a ten-year near its invalidation zone against hospital-capex sensitivity
  • Evidence quality caps conviction: institutional holdings are months stale and thin, the heavy-volume day's direction is unconfirmed, and hedge pricing could not be quoted
  • The counterweight stands: fundamentals, order growth and accumulation argue against a full exit, which is why the stance lands reduced rather than gone

QuantOrb.pro Quantitative Signals

MFI (14-day)

67.42

accumulation zone · CONTINUATION screen

qOp signal strength

CONTINUATION · 65%

quantitative screen, not a recommendation

Revenue

$1.5B

+7%

Organic growth

6%

Diluted EPS

$2.59

vs $2.34

Adjusted EPS

$2.59

vs $2.34

Money-flow and momentum readings from this run's own engine outputs (QuantOrb snapshot as cited in Sources; technicals as of the covered session) — context, not signals to act on.

Not a recommendation. A quantitative screen, not a recommendation — the 13F data are a non-exhaustive quarter-end snapshot subject to a reporting lag of up to 45 days.

qOp quant view →

Sources

Facts (verifiable): SEC filings via the QuantOrb document corpus · QuantOrb money-flow & 13F datasets. Reading (AI-powered): AdCho’s synthesis via a multi-analyst AI engine.

Sheet schema adcho.tearsheet.v1 · rendered by AdCho · freshness day 21 (D11 day-0 rule, US-session dates only)